Pregnant Women WARNED – Treatment Change!

Buprenorphine treatment for pregnant women with opioid use disorder significantly reduces the risk of preterm birth and improves infant outcomes compared to methadone, according to recent population-based studies.

At a Glance

  • Buprenorphine is associated with lower risk of preterm birth, greater birth weight, and larger head circumference compared to methadone in pregnant women with opioid use disorder
  • Quickly stopping opioids during pregnancy is not recommended due to risks like preterm labor, fetal distress, and miscarriage
  • Universal screening for substance use should be standard in comprehensive obstetric care, beginning at the first prenatal visit
  • Coordinated care between prenatal and substance use specialists is crucial for optimizing outcomes
  • Breastfeeding is encouraged for women stable on opioid agonists who aren’t using illicit drugs

Treatment Options During Pregnancy

Opioid use during pregnancy has increased dramatically in recent years, mirroring the broader opioid epidemic affecting the general population. Between 1998 and 2011, the incidence of opioid use disorder during pregnancy more than doubled, creating urgent challenges for maternal and infant health. Medical experts now strongly recommend medication for opioid use disorder (MOUD) as the standard of care for pregnant women, with methadone and buprenorphine emerging as the preferred treatment options.

The American College of Obstetricians and Gynecologists (ACOG) emphasizes that attempting to quickly discontinue opioids during pregnancy can lead to severe complications including preterm labor, fetal distress, and miscarriage. Instead, a medication-based approach combined with behavioral therapy and prenatal care offers the best chance for healthy outcomes for both mother and baby.

Buprenorphine’s Advantages Over Methadone

Recent research has revealed important differences between the two primary medications used to treat opioid use disorder during pregnancy. Buprenorphine has demonstrated several advantages over methadone in key pregnancy outcomes. Studies show that infants born to mothers treated with buprenorphine had significantly lower risks of preterm birth, greater birth weights, and larger head circumferences compared to those whose mothers received methadone treatment.

While both medications are effective for stabilizing maternal opioid use, these findings suggest that buprenorphine may offer additional protection for fetal development. Importantly, researchers have found no evidence of increased harm associated with buprenorphine compared to methadone. Both medications do carry a risk of neonatal abstinence syndrome (NAS), a condition where newborns experience withdrawal symptoms, but the potential benefits of treatment far outweigh the risks of untreated opioid use disorder.

Comprehensive Care Approach

Experts emphasize that treating opioid use disorder during pregnancy requires a multidisciplinary approach. The Centers for Disease Control and Prevention (CDC) and ACOG recommend coordination between prenatal care providers, addiction specialists, and pediatric teams. Universal screening for substance use should begin at the first prenatal visit and continue throughout pregnancy, creating opportunities for early intervention. This integrated approach helps address both the medical and psychosocial aspects of addiction.

For many women, pregnancy represents a powerful motivator for seeking treatment. Resources like SAMHSA’s National Helpline (1-800-662-HELP) provide confidential, 24/7 support for connecting with local treatment facilities, support groups, and community organizations. The service operates in both English and Spanish, with text-based support available by texting a ZIP code to 435748 (HELP4U). In 2020, the helpline saw a 27% increase in calls compared to the previous year, reflecting growing awareness and need for substance use treatment services.

Postpartum Considerations

The postpartum period presents unique challenges for women with opioid use disorder. ACOG guidelines recommend continuing medication treatment after delivery and emphasize the importance of ongoing psychosocial support for relapse prevention. For women who are stable on opioid agonist therapy and not using illicit drugs, breastfeeding is generally encouraged unless other contraindications exist. Breastfeeding can help reduce the severity of neonatal abstinence syndrome and promotes maternal-infant bonding.

Healthcare providers are increasingly moving away from punitive approaches to substance use during pregnancy, recognizing that fear of legal consequences often prevents women from seeking necessary prenatal care and addiction treatment. A supportive, non-judgmental approach focused on harm reduction has proven more effective in improving outcomes for both mothers and infants. With appropriate medication treatment and comprehensive support, many women with opioid use disorder can experience healthy pregnancies and successful recovery.

RELATED ARTICLESMORE FROM AUTHOR